Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128628 · ClinicalTrials.gov registry record · Phase 2
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
A Phase 2 study of Dry Eye Disease, sponsored by Bausch & Lomb Incorporated.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 423
- Enrollment target
- 20
- Study locations
NCT07128628 is a Phase 2 study of Dry Eye Disease that is actively recruiting participants, run by Bausch & Lomb Incorporated. The registered enrollment target is 423 participants, above the 242-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (75% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT07128628, a Phase 2 study of Dry Eye Disease, is actively recruiting participants, sponsored by Bausch & Lomb Incorporated.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 423 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG Lifitegrast/Perfluorohexyloctane Fixed Dose Combination
- DRUG Lifitegrast
- DRUG Perfluorohexyloctane
Study Locations (20)
California
- Global Research Management, Inc. - Glendale
- SoCal Eye - Lakewood Clinic - Long Beach
- LoBue Laser and Eye Medical Center - Murrieta
- Eye Research Foundation, Inc. - Newport Beach
- Wolstan and Goldberg Eye Associates - Torrance
Missouri
- Insight Eyecare Specialties, Inc. - Kansas City
- Moyes Eye Center, P.C. - Kansas City
- Ophthalmology Consultants, Ltd. - St Louis
- Comprehensive Eye Care Ltd. - Washington
Florida
- Segal Drug Trials/Office of Bruce A Segal, MD - Delray Beach
- Bowden Eye and Associates - Jacksonville
- Shettle Eye Research, Inc - Largo
Minnesota
- Vance Thompson Vision - Alexandria - Alexandria
- Complete Eye Care of Medina - Medina
New York
- Opthalmic consultants of Long Island - Garden City
- Rochester Ophthalmological Group,PC - Rochester
Arizona
- Eye Doctors of Arizona, PLLC - Phoenix
Georgia
- Clayton Eye Clinical Research, LLC - Morrow
Indiana
- Midwest Cornea Associates LLC - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 423 participants |
| Start Date | 2025-10-24 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07128628
The ClinicalTrials.gov registry entry for NCT07128628 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 423 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 242-participant average among 33 other Dry Eye Disease trials with a reported enrollment target (75% higher). The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye Disease appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT07128628 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Missouri, Florida.
Frequently Asked Questions
What is clinical trial NCT07128628 about?
NCT07128628 is a clinical study titled "A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease". A 4-Week, Randomized, Double-Masked, Parallel-Group, Active-Controlled, Multicenter Study Evaluating Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination Administered Twice Daily on Signs and Symptoms of Dry Eye Disease
What is the current status of trial NCT07128628?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 423 participants. The study started on 2025-10-24. Estimated completion is 2026-11.
What conditions does trial NCT07128628 study?
This clinical trial studies the following conditions: Dry Eye Disease.
What interventions are being tested in trial NCT07128628?
The interventions under investigation include: Vehicle (DRUG), Lifitegrast/Perfluorohexyloctane Fixed Dose Combination (DRUG), Lifitegrast (DRUG), Perfluorohexyloctane (DRUG).
Who is sponsoring clinical trial NCT07128628?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128628 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating the Safety, Tolerability, and Efficacy of GRF312 5% in Participants With Dry Eye Disease (DED).
RECRUITING · Phase 2
-
Phase 2b Controlled Study
ACTIVE NOT RECRUITING · Phase 2
-
A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease
ACTIVE NOT RECRUITING · Phase 2
-
The Study Evaluating the Efficacy and Safety of OK-101 in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
Efficacy Study of Ecabet Ophthalmic Solution in Dry Eye Disease
COMPLETED · Phase 2
-
A Study of TL-925 as a Treatment for Dry Eye Disease
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.